Susquehanna International Group, LLP Galapagos Nv Call Options Transaction History

Susquehanna International Group, LLP

$641 Billion
Q4 2024

Call Options

27 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$25.22 - $31.05 $1.38 Million - $1.7 Million	54,800 Added 106.41%	106,300 $2.92 Million
Q3 2024 Nov 14, 2024	BUY	$24.2 - $30.67 $1.25 Million - $1.58 Million	51,500 New	51,500 $1.48 Million
Q1 2024 May 07, 2024	SELL	$32.2 - $42.44 $943,460 - $1.24 Million	-29,300 Reduced 53.47%	25,500 $821,000
Q4 2023 Feb 14, 2024	BUY	$31.87 - $40.71 $1.22 Million - $1.56 Million	38,400 Added 234.15%	54,800 $2.23 Million
Q3 2023 Nov 14, 2023	BUY	$34.17 - $42.98 $560,388 - $704,872	16,400 New	16,400 $566,000
Q1 2023 May 16, 2023	SELL	$36.5 - $48.0 $47,450 - $62,400	-1,300 Reduced 3.65%	34,300 $1.33 Million
Q4 2022 Feb 14, 2023	BUY	$37.44 - $46.51 $1.09 Million - $1.35 Million	29,000 Added 439.39%	35,600 $1.58 Million
Q3 2022 Nov 14, 2022	SELL	$42.27 - $57.6 $3.69 Million - $5.03 Million	-87,400 Reduced 92.98%	6,600 $281,000
Q2 2022 Aug 15, 2022	BUY	$52.3 - $71.59 $1.53 Million - $2.09 Million	29,200 Added 45.06%	94,000 $5.25 Million
Q1 2022 May 16, 2022	BUY	$51.32 - $68.5 $2.45 Million - $3.27 Million	47,800 Added 281.18%	64,800 $4.02 Million
Q4 2021 Feb 14, 2022	BUY	$47.03 - $57.12 $413,864 - $502,656	8,800 Added 107.32%	17,000 $937,000
Q3 2021 Nov 15, 2021	SELL	$52.17 - $70.2 $912,975 - $1.23 Million	-17,500 Reduced 68.09%	8,200 $431,000
Q2 2021 Aug 11, 2021	SELL	$68.86 - $83.34 $736,802 - $891,738	-10,700 Reduced 29.4%	25,700 $1.77 Million
Q1 2021 May 17, 2021	SELL	$76.15 - $111.94 $487,360 - $716,416	-6,400 Reduced 14.95%	36,400 $2.81 Million
Q4 2020 Feb 16, 2021	SELL	$96.85 - $148.25 $629,525 - $963,625	-6,500 Reduced 13.18%	42,800 $4.24 Million
Q3 2020 Nov 16, 2020	SELL	$122.47 - $213.56 $612,350 - $1.07 Million	-5,000 Reduced 9.21%	49,300 $7 Million
Q2 2020 Aug 14, 2020	SELL	$185.52 - $231.25 $27.7 Million - $34.5 Million	-149,400 Reduced 73.34%	54,300 $10.7 Million
Q1 2020 May 15, 2020	BUY	$143.0 - $274.03 $25 Million - $48 Million	175,100 Added 612.24%	203,700 $39.9 Million
Q4 2019 Feb 14, 2020	SELL	$146.12 - $215.82 $3.99 Million - $5.89 Million	-27,300 Reduced 48.84%	28,600 $5.92 Million
Q3 2019 Nov 14, 2019	BUY	$130.44 - $187.64 $821,772 - $1.18 Million	6,300 Added 12.7%	55,900 $8.53 Million
Q2 2019 Aug 14, 2019	SELL	$111.45 - $128.93 $18.5 Million - $21.4 Million	-166,300 Reduced 77.03%	49,600 $6.4 Million
Q1 2019 May 15, 2019	BUY	$89.61 - $117.78 $18.3 Million - $24.1 Million	204,700 Added 1827.68%	215,900 $25.4 Million
Q4 2018 Feb 14, 2019	SELL	$87.81 - $110.65 $1.1 Million - $1.38 Million	-12,500 Reduced 52.74%	11,200 $1.03 Million
Q3 2018 Nov 14, 2018	BUY	$90.63 - $120.22 $1.13 Million - $1.5 Million	12,500 Added 111.61%	23,700 $2.67 Million
Q2 2018 Aug 14, 2018	SELL	$88.4 - $105.34 $114,920 - $136,942	-1,300 Reduced 10.4%	11,200 $1.03 Million
Q1 2018 May 15, 2018	BUY	$94.51 - $120.23 $992,355 - $1.26 Million	10,500 Added 525.0%	12,500 $1.25 Million
Q3 2017 Nov 14, 2017	BUY	$73.17 - $103.47 $146,340 - $206,940	2,000	2,000 $204,000

Others Institutions Holding GLPG

# of Institutions

Shares Held

13.2M

Call Options Held

213K

Put Options Held

126K

Tang Capital Management LLC San Diego, CA

2.16M
Shares

$57.7 Million
4.46% of portfolio
Bvf Inc San Francisco, CA

1.57M
Shares

$41.9 Million
1.62% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

1.41M
Shares

$37.7 Million
0.96% of portfolio
Prosight Management, LP Dallas, TX

1.03M
Shares

$27.4 Million
8.37% of portfolio
Deep Track Capital, LP Greenwich, CT

781K
Shares

$20.8 Million
0.95% of portfolio

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.76B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account